化疗前后卵巢肿瘤中的金属硫蛋白水平。
Metallothionein levels in ovarian tumours before and after chemotherapy.
作者信息
Murphy D, McGown A T, Crowther D, Mander A, Fox B W
机构信息
CRC Department of Medical Oncology, Paterson Institute for Cancer Research, Christie Hospital, Withington, Manchester, UK.
出版信息
Br J Cancer. 1991 May;63(5):711-4. doi: 10.1038/bjc.1991.160.
Abstract
The metallothionein content of ovarian tumours is considerably higher than that found in normal ovaries (greater than 100-fold differences in mean values, P less than 0.001). There was no difference between the metallothionein content of tumours from patients who had completed chemotherapy, usually with a regimen containing a platinum drug, and tumours from untreated patients. Similarly, the level of metallothionein was not influenced by response to therapy, age, stage, histology, or tumour cell differentiation state. These data do not support the hypothesis that metallothionein content is a major determinant of tumour sensitivity in ovarian cancer.
摘要
卵巢肿瘤中的金属硫蛋白含量显著高于正常卵巢中的含量（平均值差异大于100倍，P<0.001）。完成化疗（通常采用含铂类药物的方案）的患者肿瘤中的金属硫蛋白含量与未治疗患者的肿瘤中的金属硫蛋白含量没有差异。同样，金属硫蛋白水平不受治疗反应、年龄、分期、组织学或肿瘤细胞分化状态的影响。这些数据不支持金属硫蛋白含量是卵巢癌肿瘤敏感性主要决定因素的假说。
相似文献
1
Metallothionein levels in ovarian tumours before and after chemotherapy.化疗前后卵巢肿瘤中的金属硫蛋白水平。
Br J Cancer. 1991 May;63(5):711-4. doi: 10.1038/bjc.1991.160.
2
Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.对于先前接受过卡铂-环磷酰胺治疗的卵巢癌患者，采用顺铂-异环磷酰胺进行二线化疗。
J Chemother. 1999 Apr;11(2):144-9. doi: 10.1179/joc.1999.11.2.144.
3
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.多药化疗方案在卵巢癌中的重要性：剂量强度分析
J Natl Cancer Inst. 1993 Nov 3;85(21):1732-42. doi: 10.1093/jnci/85.21.1732.
4
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.美法仑与顺铂联合化疗作为晚期卵巢癌初始治疗的随机试验：初步及长期结果——东部肿瘤协作组E2878研究
Cancer. 1996 Feb 15;77(4):733-42.
5
Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.卵巢癌肉瘤：临床病理预后因素及含铂化疗方案的评估
Gynecol Oncol. 2008 Jan;108(1):136-40. doi: 10.1016/j.ygyno.2007.09.003. Epub 2007 Oct 23.
6
Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.晚期卵巢癌的化疗：基于随机试验的当前护理标准
Gynecol Oncol. 1994 Dec;55(3 Pt 2):S97-107. doi: 10.1006/gyno.1994.1347.
7
[Ovarian malignant tumours. Efficacy of germ cell and sex cord tumour treatment protocol in Poland].[卵巢恶性肿瘤。波兰生殖细胞和性索肿瘤治疗方案的疗效]
Med Wieku Rozwoj. 2006 Jul-Sep;10(3 Pt 1):803-10.
8
Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
Int J Clin Oncol. 2006 Jun;11(3):163. doi: 10.1007/s10147-006-0572-7.
9
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.卵巢癌患者中对化疗反应及DNA修复具有潜在重要性的基因表达
Gynecol Oncol. 1997 Apr;65(1):130-7. doi: 10.1006/gyno.1996.4609.
10
Effect of carboplatin based combination chemotherapy on ovarian cancer.
Chin Med J (Engl). 1996 May;109(5):349-52.
引用本文的文献
1
Molecular characteristics and tumorigenicity of ascites-derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer.腹水来源肿瘤细胞的分子特征和致瘤性：线粒体氧化磷酸化作为卵巢癌的一个新的治疗靶点。
Mol Oncol. 2021 Dec;15(12):3578-3595. doi: 10.1002/1878-0261.13028. Epub 2021 Jun 18.
2
Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.金属硫蛋白 - 免疫组织化学癌症生物标志物：荟萃分析。
PLoS One. 2014 Jan 8;9(1):e85346. doi: 10.1371/journal.pone.0085346. eCollection 2014.
3
Down-regulation of metallothionein 1 and 2 after exposure to electromagnetic field in mouse testis.小鼠睾丸暴露于电磁场后金属硫蛋白1和2的表达下调。
Iran Biomed J. 2011;15(4):151-6. doi: 10.6091/ibj.926.2012.
4
Localization of metallothionein in breast carcinomas. An immunohistochemical study.
Virchows Arch A Pathol Anat Histopathol. 1993;423(3):215-9. doi: 10.1007/BF01614773.
5
Cell cycle regulation of metallothionein in human colonic cancer cells.人结肠癌细胞中金属硫蛋白的细胞周期调控
Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):579-83. doi: 10.1073/pnas.92.2.579.
6
Metallothionein expression in human breast cancer.金属硫蛋白在人类乳腺癌中的表达。
Br J Cancer. 1995 Oct;72(4):968-72. doi: 10.1038/bjc.1995.443.
本文引用的文献
1
Resistance against cis-dichlorodiammineplatinum in cultured cells with a high content of metallothionein.在具有高含量金属硫蛋白的培养细胞中对顺二氯二氨铂的抗性。
Toxicol Appl Pharmacol. 1981 Nov;61(2):215-26. doi: 10.1016/0041-008x(81)90411-7.
2
Application of a modified 203Hg binding assay for metallothionein.改良的203汞结合试验在金属硫蛋白检测中的应用。
Life Sci. 1983 Apr 4;32(14):1629-36. doi: 10.1016/0024-3205(83)90870-6.
3
The human metallothionein gene family: structure and expression.人类金属硫蛋白基因家族：结构与表达
Environ Health Perspect. 1984 Mar;54:111-5. doi: 10.1289/ehp.8454111.
4
Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cis-dichlorodiammineplatinum.来自具有高含量金属硫蛋白的细胞系的肿瘤对顺二氯二氨铂表现出增强的抗性。
Acta Pharmacol Toxicol (Copenh). 1984 Sep;55(3):183-7. doi: 10.1111/j.1600-0773.1984.tb02034.x.
5
Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells.金属硫蛋白介导的人卵巢癌细胞顺铂耐药性
Cancer Chemother Pharmacol. 1987;19(2):149-54. doi: 10.1007/BF00254568.
6
7
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II).一株对顺二氯二氨铂（II）耐药的人鳞状癌细胞系的特性分析
Cancer Res. 1987 Jan 15;47(2):388-93.
8
Overexpression of metallothionein confers resistance to anticancer drugs.金属硫蛋白的过表达赋予对抗癌药物的抗性。
Science. 1988 Sep 30;241(4874):1813-5. doi: 10.1126/science.3175622.
9
Gynecologic malignancies.妇科恶性肿瘤
Cancer Chemother Biol Response Modif. 1988;10:291-312.
10
Overexpressed human metallothionein IIA gene protects Chinese hamster ovary cells from killing by alkylating agents.过表达的人金属硫蛋白IIA基因可保护中国仓鼠卵巢细胞免受烷化剂的杀伤。
Proc Natl Acad Sci U S A. 1990 Apr;87(7):2710-4. doi: 10.1073/pnas.87.7.2710.
Zotero 插件